Skip to main content

Sepsis Diagnostics Market Set to Soar Past USD 1.30 Billion by 2030 | Skyquest Technology

In the dynamic realm of sepsis diagnostics, cutting-edge technologies like Blood Culture and Immunoassays are driving progress. With a focus on applications in Hospitals and Diagnostics Centers, industry experts forecast substantial growth and share for this sector from 2023 to 2030.

Westford,USA, Jan. 09, 2024 (GLOBE NEWSWIRE) — The global Sepsis Diagnostics market size is expected to reach USD 1.30 billion by 2030 and exhibit a CAGR of 9.8% in the forecast period (2023−2030), according to Skyquest’s latest research report. The rising prevalence of sepsis cases worldwide, the need for rapid and accurate diagnostic methods to improve patient outcomes, increasing awareness among healthcare professionals about the importance of early sepsis detection, and advancements in diagnostic technologies such as biomarker assays and molecular diagnostics are fueling the market’s growth.

According to SkyQuest’s latest global research of the Sepsis Diagnostics market, growing emphasis on point-of-care testing for sepsis in emergency departments and critical care settings, the development of novel biomarkers and molecular diagnostic methods for sepsis detection, an increasing focus on early prediction and risk stratification of sepsis to improve patient outcomes, the integration of artificial intelligence (AI) and machine learning in sepsis diagnostics for more accurate and rapid results are the trends that aid in the market’s growth.

Browse in-depth TOC on “Sepsis Diagnostics Market”

  • Pages – 157
  • Tables – 59
  • Figures -75

Sepsis diagnostic is the process of identifying sepsis patients. Sepsis is a life-threatening condition that arises when the body’s response to an infection damages its own tissues and organs. Early detection and treatment of sepsis is critical to improving patient outcomes.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/sepsis-diagnostics-market

Prominent Players in Sepsis Diagnostics Market

  • Abbott Laboratories
  • Becton, Dickinson and Company (BD)
  • bioMérieux
  • Cepheid
  • Danaher Corporation (Beckman Coulter Life Sciences)
  • DiaSorin
  • EKF Diagnostics
  • Fujifilm
  • Hologic, Inc
  • Hycult Biotech
  • Luminex Corporation
  • Meridian Bioscience
  • Mesa Biotech
  • MilliporeSigma
  • Mindray
  • Nanosphere Health Sciences
  • Ortho Clinical Diagnostics
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

Report Scope & Segmentation:

Attributes

 

Details

 

Forecast Period

 

2023-2030
Market Size in 2022

 

 0.67 Billion
2030 Value Projection

 

1.30 Billion
CAGR9.8%
Segments Covered

 

 

 

 

  • Technology

Blood Culture Technology and Immunoassays

  • Application

Hospitals and Diagnostics Centres

 

 

 

Regions Covered

 

 

North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)

Blood Culture Media Demand to Grow Substantially in the Forecast Period

Blood culture media dominate the global online market as they are essential for isolating and identifying microorganisms in blood samples, which is a critical step in diagnosing sepsis. These products are fundamental in the early detection and identification of pathogens responsible for sepsis, helping healthcare providers initiate timely treatment.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/sepsis-diagnostics-market

Healthcare Facilities are the Leading Application Segment

In terms of application, healthcare facilities are the leading segment as it is often associated with healthcare-associated infections, and hospitals are where a significant proportion of sepsis cases are diagnosed and treated. Patients in intensive care units (ICUs) and other critical care settings are particularly vulnerable to sepsis.

North America is the leading Market Due to the Technological Advancements

Region-wise, North America is one of the largest growing markets with a huge emphasis on technological advancements. The region also had a relatively high incidence of sepsis cases, partly due to an aging population and the prevalence of chronic illnesses. Robust research and development activities, along with regulatory support, contributed to advancements in sepsis diagnostics technology.

A recent report thoroughly analyzes the major players operating within the Sepsis Diagnostics market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavours to develop innovative solutions that cater to the ever-increasing demand for Sepsis Diagnostics.

Key Developments in Sepsis Diagnostics Market

  • In May 2023, BioFire Diagnostics announced the launch of its FilmArray BCID2 Panel, a sepsis diagnostic assay that can detect over 40 bacterial and fungal pathogens.
  • In April 2023, GenMark Diagnostics announced the launch of its ePlex Blood Culture ID Panel, a diagnostic assay that can detect over 40 bacterial and fungal pathogens associated with sepsis.
  • In March 2023, Sysmex Corporation announced a partnership with Nephron Pharmaceuticals to develop a rapid diagnostic test for sepsis that can be used at the point-of-care.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/sepsis-diagnostics-market

Key Questions Answered in Sepsis Diagnostics Market Report

  • What specific growth drivers will impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Industrial Radiography Market

Global Optical Preclinical Imaging Market

Global Film Dressing Market

Global Electrosurgical Generators Market

Global Hemostasis Products Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.